Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + Carboplatin in Advanced Triple-Negative Breast Cancer
NCT02993094Phase 2Terminated
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Nov 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in triple-negative breast cancer (TNBC), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Started Nov 2016; status: terminated.
02
Drugs
ixazomib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02993094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993094.